Expression and structure of interleukin 4 receptor (IL-4R) complex in human invasive pituitary adenomas.
Pituitary adenomas are frequently invasive of surrounding tissues, which adversely affects the surgical outcome and the disease-free survival of patients. In the present study, Interleukin 4 receptor (IL-4R) complex has been investigated to figure out whether the three subunits are overexpressed in human invasive pituitary adenomas. Reverse transcription-polymerase chain reaction (RT-PCR) analysis for interleukin 4 receptor alpha (IL-4Ralpha), interleukin 13 receptor alpha1 (IL-13Ralpha1), interleukin 2 receptor gammac (IL-2Rgammac) were performed on total RNA extracted from 10 non-invasive pituitary adenomas, 30 invasive pituitary adenomas, one glioblastoma multiforme, one normal human pituitary tissue sample and one normal human brain tissue sample. Quantitative real-time PCR and in situ immunofluorescence assay were performed in five invasive functioning pituitary adenoma samples and five invasive nonfunctioning pituitary adenoma samples. RT-PCR analysis for IL-4Ralpha, IL-13Ralpha1 and IL-2Rgammac chains were overexpressed in invasive pituitary adenomas. The transcripts for three subunits were not/weakly expressed in normal pituitary tissue and normal brain tissue. The quantitative real-time PCR and in situ immunofluorescence assay confirmed the results of the RT-PCR analysis. Our results indicate that human invasive pituitary adenomas express type III IL-4R complex. These receptors may serve as a novel target for immunotoxin therapy in patients with invasive pituitary adenomas who are not amenable to total surgical resection or for recurrent cases.
Chen
Lukui
L
Department of Neurosurgery, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 361004, China. neuro.clk@yahoo.com.cn
Liu
Yunsheng
Y
Hou
Yonghong
Y
Kato
Yoko
Y
Sano
Hirotoshi
H
Kanno
Tetsuo
T
D000236:Adenoma / Q000175:diagnosis / Q000276:immunology* / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000737:chemistry / Q000235:genetics*; D005455:Fluorescent Antibody Technique; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D053631:Interleukin Receptor Common gamma Subunit / Q000235:genetics; D053661:Interleukin-13 Receptor alpha1 Subunit / Q000235:genetics; D009361:Neoplasm Invasiveness / Q000175:diagnosis / Q000235:genetics / Q000276:immunology; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000276:immunology* / Q000378:metabolism*; D011237:Predictive Value of Tests; D021122:Protein Subunits / Q000032:analysis / Q000737:chemistry / Q000235:genetics*; D012333:RNA, Messenger / Q000032:analysis / Q000378:metabolism; D019948:Receptors, Interleukin-4 / Q000032:analysis / Q000737:chemistry / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D014408:Biomarkers, Tumor; C507941:IL2RG protein, human; D053631:Interleukin Receptor Common gamma Subunit; D053661:Interleukin-13 Receptor alpha1 Subunit; D021122:Protein Subunits; D012333:RNA, Messenger; D019948:Receptors, Interleukin-4